Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation
Novo Nordisk (NYSE: NVO) announced a strategic partnership with Vivtex Corporation to co-develop next‑generation oral biologic...
3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), announced that...
Kexing Biopharma’s GB19 Wins NMPA IND Approval – Novel BDCA2 Targeted Therapy for Lupus Enters Clinic
Kexing Biopharma (SHA: 688136) announced that China’s National Medical Products Administration (NMPA) has cleared GB19 Injection...
Lepu Biopharma’s GPC3 ADC MRG006A Wins NMPA Approval for HCC Combination Trials – First‑in‑Class Asset Advances
Lepu Biopharma Co., Ltd (HKG: 2157) announced that China’s National Medical Products Administration (NMPA) has approved...
GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235
GlaxoSmithKline (GSK, NYSE: GSK) announced a definitive agreement to acquire 35Pharma Inc., a Canada‑based clinical‑stage biopharmaceutical...
FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen
AstraZeneca (AZ, NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved the...
Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label
Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has...
Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
Astellas Pharma Inc. (TYO: 4503) and Vir Biotechnology, Inc. (NASDAQ: VIR) announced a global strategic collaboration to...
Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
Bio-Thera Solutions Inc. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has accepted the...
MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
MGI Tech (SHA: 688114) announced the sale of 100% equity in its US subsidiary, Complete Genomics...
Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced a strategic collaboration with Antengene Corporation Limited...
AbbVie Invests $380M in Illinois API Manufacturing – AI‑Enabled Facilities for Neuroscience and Obesity Drugs
AbbVie (NYSE: ABBV) announced a USD 380 million investment to build two new active pharmaceutical ingredient (API) manufacturing...
Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development
Dartsbio Pharmaceuticals announced an exclusive licensing agreement with Slate Medicines, Inc., a US‑based emerging biopharmaceutical...
Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced an exclusive license agreement with Abbott for the commercialization...
SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic
SinoMab BioScience Limited (HKG: 3681) announced that China’s National Medical Products Administration (NMPA) has approved the...
Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...
Pharscin Pharma’s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval – First Class 1.1 Innovative Drug Enters Clinic
Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that China’s National Medical Products Administration (NMPA) has...
CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years
CanSino Biologics (HKG: 6185) announced that China’s National Medical Products Administration (NMPA) has approved a supplementary...